Objective: Comparison of serum IL-6 levels in Parkinson’s disease (PD) patients with and without Сovid-19.

Background: Scientists say that the infectious agent SARS-CoV-2 increases the production of IL-6 and IL-6, while the production of TNF-α and IL-1 at moderate and low levels does not change significantly. IL-6 is a prognostic marker of disease outcome and survival.

Method: A total of 90 patients with PD were examined. Patients with PD were divided into 2 groups. Group 1 consisted of 45 patients with PD and Covid-19 infection, and group 2 consisted of 45 patients with PD and no Сovid-19 infection. The control group was patients who underwent Covid-19 without PВ. The amount of IL-6 was checked using the IFA method.

Results: A total of 90 patients with PD had an average serum IL-6 level of 15.49±4.4 pg/ml, while in the control group, it was found to be 5.78±3.8 pg/ml. . It was found that the amount of IL-6 increased almost 2.7 times in the main group compared to the control group (r<0.001). It was found that the IL-6 content of serum of patients with Covid-19 in group 1 was 21.37±5.5 pg/ml, and it was reliably different from the control group, r≤0.001. It was found that the IL-6 content of blood serum of patients who did not have Covid-19 in group 2 was 12.91±4.7 pg/ml, and it was reliably different from the control group, r≤0.001. Also, the IL-6 content of blood serum of patients who underwent Covid-19 in group 1 and patients who did not undergo Covid-19 in group 2 differed reliably, r≤0.001.​

Conclusion: Changes in the treatment after infection with Covid-19 are related to the amount of cytokines in the blood serum of patients, including the level of IL-6. Elevated levels of this cytokine may indicate disease severity in PD patients.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/altered-levels-of-interleukin-6-in-parkinsons-disease-patients-with-and-without-covid-19/